This Plain language summary of publication article, published in Future Oncology, provides a breakdown of the strategies used in the MajesTEC-1 study to manage side effects that may occur with teclistamab treatment.
Plain Language Summary
What is this summary about?
This summary describes management of two side effects in the MajesTEC-1 clinical study, which tested the cancer drug teclistamab in participants with multiple myeloma. These side effects were cytokine release syndrome (CRS) and infections.
What were the results?
In the MajesTEC-1 study, 63% of participants had their multiple myeloma improve; 72% of participants developed CRS, and 80% had an infection. CRS was mostly low grade, occurred during the initial stage when participants received lower teclistamab doses, and was…